Acute lymphoblastic leukemia is the most common cancer in children and adolescents. While current treatments have resulted in 85-90% cure, the remaining 10-15% cases represent the leading causes of childhood cancer mortality. This is largely due to specific leukemia subtypes being resistant to treatment. One of these subtypes is hypodiploid B cell leukemia characterized by multiple chromosomal losses. For these patients, treatment options remain limited, and their prognosis is dim.
1. How to integrate genomics and proteomics profiling with drug screens to identify potential therapeutic targets
2. How to move from in vitro to in vivo preclinical studies to inform new clinical trials.
3. The audience will learn about hypodiploidy: from cytogenetics to prognosis to drug response in the context of leukemia.